Plasma cells – a key target in antibody-mediated diseases
5 affiliations
- 1German Rheumatology Research Center (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany
- 2Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany
- 3Faculty of Medicine, Tottori University, Yonago, Japan
- 4German Center for Child and Adolescent Health (DZKJ), Berlin, Germany
- 5Technical University Berlin (TU Berlin), Institute of Biotechnology, Berlin, Germany
Abstract
Plasma cells are central to humoral immunity and antibody-mediated diseases. Persistent long-lived plasma cells, mostly residing in the bone marrow, have the potential to drive chronicity of such diseases and refractoriness to classical therapeutic approaches, based on targeting ongoing immune reactions. Here we discuss recent progress in understanding critical extrinsic survival signals and intrinsic signaling pathways for survival of long-lived plasma cells, their redundancy, diversity and integration. The apparent heterogeneity of long-lived plasma cells and their niches across developmental origins and isotypes, and tissues of residency, may offer new options for selective therapeutic interventions. A spectrum of therapeutic strategies is evolving, ranging from generic, to selective and finally to antigen-specific ablation of plasma cells.
Related
- Systemic antibody repertoires target specific microbial antigens in patients with colorectal cancer
- 133 In vitro comparison of the stability and biotransformation of sac-TMT and control antibody-drug conjugates in human plasma
- Target Discovery and Drug Intervention in Inflammatory Diseases： A Paradigm Shift from Mechanistic Dissection to Precision Therapy
- Limited cross strain CMV protection by a bivalent (gB/pp65) vaccine is based on an impaired gB antibody response and evasion of pp65 cell mediated immunity
- Distinct profiles and antibody production by splenic and lymph node antibody-secreting cells in Trypanosoma cruzi infection
BibTeX
@article{fiebig2026plasma,
title = {{Plasma cells – a key target in antibody-mediated diseases}},
author = {Leonard Fiebig and Tobias Alexander and Koji Tokoyoda and Thomas Dörner and Henrik E. Mei and Falk Hiepe and Mir-Farzin Mashreghi and Anja E. Hauser and Hyun-Dong Chang and Andreas Radbruch},
journal = {Cellular and Molecular Life Sciences: CMLS},
year = {2026},
month = oct,
doi = {10.1007/s00018-026-06496-4},
url = {https://doi.org/10.1007/s00018-026-06496-4},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Plasma cells – a key target in antibody-mediated diseases
AU - Leonard Fiebig
AU - Tobias Alexander
AU - Koji Tokoyoda
AU - Thomas Dörner
AU - Henrik E. Mei
AU - Falk Hiepe
AU - Mir-Farzin Mashreghi
AU - Anja E. Hauser
AU - Hyun-Dong Chang
AU - Andreas Radbruch
PY - 2026
DA - 2026/10/23
JO - Cellular and Molecular Life Sciences: CMLS
DO - 10.1007/s00018-026-06496-4
UR - https://doi.org/10.1007/s00018-026-06496-4
AB - Plasma cells are central to humoral immunity and antibody-mediated diseases. Persistent long-lived plasma cells, mostly residing in the bone marrow, have the potential to drive chronicity of such diseases and refractoriness to classical therapeutic approaches, based on targeting ongoing immune reactions. Here we discuss recent progress in understanding critical extrinsic survival signals and intrinsic signaling pathways for survival of long-lived plasma cells, their redundancy, diversity and integration. The apparent heterogeneity of long-lived plasma cells and their niches across developmental origins and isotypes, and tissues of residency, may offer new options for selective therapeutic interventions. A spectrum of therapeutic strategies is evolving, ranging from generic, to selective and finally to antigen-specific ablation of plasma cells.
SN - 1420-682X
SN - 1420-9071
ER -